New combo therapy shows promise for rare thymic cancer

NCT ID NCT03463460

Ongoing Disease control Sponsor: Dwight Owen Source: ClinicalTrials.gov ↗

First seen Apr 23, 2026 · Last updated May 23, 2026 · Updated 7 times

Summary

This phase II trial tested a combination of two drugs, pembrolizumab and sunitinib, in 9 people with advanced thymic carcinoma that had spread or couldn't be removed and no longer responded to standard chemotherapy. The goal was to see if the combination could shrink tumors or stop them from growing. Pembrolizumab helps the immune system attack cancer cells, while sunitinib blocks enzymes that help tumors grow. The study is now complete and not recruiting new participants.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for THYMIC CARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Indiana University

Indianapolis, Indiana, 46202, United States
Moffitt Cancer Center

Tampa, Florida, 33612, United States
Ohio State University Comprehensive Cancer Center

Columbus, Ohio, 43210, United States

Conditions

Explore the condition pages connected to this study.

THYMIC CARCINOMA